skip to main content
Lingue:

Development of Drugs to Target Interactions Between Leukocytes and Endothelial Cells and Treatment Algorithms for Inflammatory Bowel Diseases

Danese, Silvio ; Panés, Julián

Gastroenterology, November 2014, Vol.147(5), pp.981-989 [Rivista Peer Reviewed]

Fulltext non disponibile

Vedi tutte le versioni
Citazioni Citato da
  • Titolo:
    Development of Drugs to Target Interactions Between Leukocytes and Endothelial Cells and Treatment Algorithms for Inflammatory Bowel Diseases
  • Autore: Danese, Silvio ; Panés, Julián
  • Note di contenuto: Increased understanding of the pathogenesis of inflammatory bowel diseases (IBDs) has led to new therapeutic strategies. One of these is to target the molecules that regulate interactions between leukocytes and endothelial cells at sites of inflammation (mainly leukocyte integrins and endothelial cell adhesion molecules of the immunoglobulin superfamily). These molecules have been validated as therapeutic targets for IBD; several have shown efficacy, and 2 have been approved by the Food and Drug Administration for treatment of IBD. Natalizumab, the first anti-integrin antibody tested for treatment of IBD, blocks the α4 subunit. Although it is effective, its clinical use has been limited by its association with risk of progressive multifocal leukoencephalopathy. Other, allegedly more selective drugs that affect leukocyte recruitment in the gastrointestinal tract have been developed or are under investigation and could increase safety. These include vedolizumab and AMG 181 (antibodies...
  • Fa parte di: Gastroenterology, November 2014, Vol.147(5), pp.981-989
  • Soggetti: Immune Regulation ; Crohn’s Disease ; Ulcerative Colitis ; Drug Development ; Immune Regulation ; Crohn’s Disease ; Ulcerative Colitis ; Drug Development ; CD ; Cdai ; CNS ; Ibd ; Ig ; Jcv ; Madcam-1 ; Pml ; Tnf ; Vcam-1
  • Lingua: Inglese
  • Tipo: Articolo
  • Identificativo: ISSN: 0016-5085 ; E-ISSN: 1528-0012 ; DOI: 10.1053/j.gastro.2014.08.044

Ricerca in corso nelle risorse remote ...